The Food and Drug Administration (FDA) has approved a treatment for the prevention of RSV among infants and toddlers, making it the first preventive drug for the common virus that surged last winter among small children. The FDA approved nirsevimab-alip, or Beyfortus, for the prevention of RSV among newborns and infants born during or entering into their first RSV season, which typically starts in the fall, peaks in the winter and ends in the spring. Beyfortus is a monoclonal antibody administered in one dose. The safety of efficacy of the medicine is supported by three clinical trials, according to the FDA's release on Monday.
Hence then, the article about fda approves preventive rsv treatment for infants and toddlers was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( FDA approves preventive RSV treatment for infants and toddlers )